Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

G Petroni, LC Cantley, L Santambrogio… - Nature Reviews …, 2022 - nature.com
A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti - Drug Resistance Updates, 2021 - Elsevier
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

[HTML][HTML] Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy

HT Chen, H Liu, MJ Mao, Y Tan, XQ Mo, XJ Meng… - Molecular cancer, 2019 - Springer
Autophagy is a highly conserved catabolic process that mediates degradation of pernicious
or dysfunctional cellular components, such as invasive pathogens, senescent proteins, and …

Progenitors from the central nervous system drive neurogenesis in cancer

P Mauffrey, N Tchitchek, V Barroca, AP Bemelmans… - Nature, 2019 - nature.com
Autonomic nerve fibres in the tumour microenvironment regulate cancer initiation and
dissemination, but how nerves emerge in tumours is currently unknown. Here we show that …

[HTML][HTML] PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy …

L Chang, PH Graham, J Hao, J Ni, J Bucci… - Cell death & …, 2014 - nature.com
Abstract The PI3K/Akt/mTOR pathway has a central role in cancer metastasis and
radiotherapy. To develop effective therapeutics to improve radiosensitivity, understanding …

[HTML][HTML] Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside

Y Liu, Y Wang, S Sun, Z Chen, S Xiang, Z Ding… - … hematology & oncology, 2022 - Springer
Epithelial cell adhesion molecule (EpCAM) functions not only in physiological processes but
also participates in the development and progression of cancer. In recent decades …

[HTML][HTML] IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways

S Duan, W Huang, X Liu, X Liu, N Chen, Q Xu… - Journal of Experimental …, 2018 - Springer
Background Inosine 5′-monophosphate dehydrogenase type II (IMPDH2) was originally
identified as an oncogene in several human cancers. However, the clinical significance and …

Programmed cell death, from a cancer perspective: an overview

AP Mishra, B Salehi, M Sharifi-Rad, R Pezzani… - Molecular diagnosis & …, 2018 - Springer
Programmed cell death (PCD) is probably the most widely discussed subject among the
topics of cancer therapy. Over the last 2 decades an astonishing boost in our perception of …

Targeting PI3K/Akt signaling in prostate cancer therapy

M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2023 - Springer
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance

L Chang, PH Graham, J Ni, J Hao, J Bucci… - Critical reviews in …, 2015 - Elsevier
Abstract The phosphatidylinositol-3-kinase/Akt and the mammalian target of rapamycin
(PI3K/Akt/mTOR) pathway is one of the most frequently activated signaling pathways in …